EGFR and adenocarcinoma: In patients with non-adenocarcinoma (ADC) non-small cell lung cancer carrying EFGR mutations, clinical studies have shown that the median OS of patients treated with EGFR-TKIs is significantly higher than patients not treated with EGFR-TKIs, and there is no significant difference in clinical characteristics between patients who respond to EGFR-TKIs and those who do not (8).